d(GC) - Association of Biotechnology and Pharmacy

More documents

Recommendations

Info

Current Trends in Biotechnology and Pharmacy Vol. 6 (2) 119-144 April 2012, ISSN 0973-8916 (Print), 2230-7303 (Online) References 1. National Human Genome Research Institute, National Institutes of Health. The Human Genome Project Completion: Frequently Asked Questions. http:// www.genome.gov/11006943 Accessed 31, Jan 2012 2. Zhang, J., Chiodini, R., Badr, A. and Zhang, G. (2011). The impact of next-generation sequencing on genomics. J Genet Genomics, 38: 95-109. 3. Check Hayden, E. The $1,000 genome: are we there yet? ; http://blogs.nature.com/ news/2012/01/the-1000-genome-are-wethere-yet.html Accessed 31, Jan 2012 4. National Human Genome Research Institute, National Institutes of Health. Director’s Page Archive: Vanity Genomes and the Future of Medical Sequencing. http://www.genome.gov/27543503 Accessed 31, Jan 2012 5. Ginsberg, G.S. and Willard, H.F. (2010). Essentials of Genomics and Personalized Medicine (1st edition), Academic Press Elsevier, San Diego, CA, USA, pp. 1. 6. National Cancer Institute, National Institutes of Health.; http://www.cancer.gov/ dictionary/?CdrID=561717 Accessed 31, Jan 2011 7. Offit, K. (2011). Personalized medicine: new genomics, old lessons. Hum Genet, 130: 3-14. 8. International Agency for Cancer Research. GLOBOCAN 2008 Database FastStats. http://globocan.iarc.fr/factsheets/ populations/factsheet.asp?uno=900 Accessed 31, Aug 2011 9. Jemal, A., Bray, F., Center, M.M., Ferlay, J., Ward, E., and Forman, D. (2011). Global cancer statistics. CA Cancer J Clin, 61: 69- 90. 10. Patel, J.D., Galsky, M.D., Chagpar, A.B., Pyle, D., and Loehrer, P.J., Sr. (2011). Role Rebecca E. Smith and Juan Miguel Pascale 136 of American Society of Clinical Oncology in low- and middle-income countries. J Clin Oncol, 29: 3097-102. 11. World Health Organization. Cancer Fact Sheet Number 279 http://www.who.int/ mediacentre/factsheets/fs297/en/ Accessed 31, Aug 2011 12. World Health Organization. Improving Cancer Control in Developing Countries. http://www.who.int/mediacentre/ multimedia/podcasts/2010/ cancer_20101019/en/ Accessed 31, Aug 2011 13. International Atomic Energy Agency. A Silent Crisis: Cancer Treatment in Developing Countries. http:// cancer.iaea.org/documents/Ref9- Treating_cancer_A_Silent_Crisis.pdf Accessed 31, Jan 2012 14. International Agency for Research on Cancer. Monographs on the Evaluation of Carcinogenic Risks to Humans: Volume 100B. http://monographs.iarc.fr/ENG/ C l a s s i f i c a t i o n / ClassificationsGroupOrder.pdf Accessed 31, Aug 2011 15. Garber, M.E., Troyanskaya, O.G., Schluens, K., Petersen, S., Thaesler, Z., Pacyna-Gengelbach, M., van de Rijn, M., Rosen, G.D., Perou, C.M., Whyte, R.I., Altman, R.B., Brown, P.O., Botstein, D., and Petersen, I. (2001). Diversity of gene expression in adenocarcinoma of the lung. Proc Natl Acad Sci U S A, 98: 13784-9. 16. International Agency for Cancer Research. GLOBOCAN Database. http:// globocan.iarc.fr/ Accessed 31, Aug 2011 17. Berger, M.F., Lawrence, M.S., Demichelis, F., Drier, Y., Cibulskis, K., Sivachenko, A.Y., Sboner, A., Esgueva, R., Pflueger, D., Sougnez, C., Onofrio, R., Carter, S.L., Park, K., Habegger, L., Ambrogio, L., Fennell, T., Parkin, M., Saksena, G., Voet, D., Ramos,
Current Trends in Biotechnology and Pharmacy Vol. 6 (2) 119-144 April 2012, ISSN 0973-8916 (Print), 2230-7303 (Online) A.H., Pugh, T.J., Wilkinson, J., Fisher, S., Winckler, W., Mahan, S., Ardlie, K., Baldwin, J., Simons, J.W., Kitabayashi, N., MacDonald, T.Y., Kantoff, P.W., Chin, L., Gabriel, S.B., Gerstein, M.B., Golub, T.R., Meyerson, M., Tewari, A., Lander, E.S., Getz, G., Rubin, M.A., and Garraway, L.A. (2011). The genomic complexity of primary human prostate cancer. Nature, 470: 214- 20. 18. Sreenath, T.L., Dobi, A., Petrovics, G., and Srivastava, S. (2011). Oncogenic activation of ERG: A predominant mechanism in prostate cancer. J Carcinog, 10: 37. 19. Tan, S.H., Petrovics, G., and Srivastava, S. (2011). Highlights from the prostate cancer genome report. Asian J Androl, 13: 659-60. 20. Dunn, T.A., Fedor, H.L., De Marzo, A.M., and Luo, J. (2012). Molecular profiling of indolent human prostate cancer: tackling technical challenges to achieve high-fidelity genome-wide data. Asian J Androl, Epub ahead of print. 21. Travis, W., Brambilla, E., Muller-Hermeling, K., and Harris, C.C. (2000). World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart., IARC Press, Lyon, France, pp. 9-124. 22. Martin, P., Kelly, C.M., and Carney, D. (2006). Epidermal growth factor receptortargeted agents for lung cancer. Cancer Control, 13: 129-40. 23. Travis, W.D., Travis, L.B., and Devesa, S.S. (1995). Lung cancer. Cancer, 75: 191-202. 24. Petersen, I. (2010). The morphological and molecular diagnosis of lung cancer. Dtsch Arztebl Int, 108: 525-31. 25. Adamo, V., Franchina, T., Adamo, B., Denaro, N., Gambadauro, P., Chiofalo, G., Scimone, A., Caristi, N., Russo, A., and Giordano, A. (2009). Gefitinib in lung cancer therapy: clinical results, predictive markers Developing world personalized cancer medicine 137 of response and future perspectives. Cancer Biol Ther, 8: 206-12. 26. Lynch, T.J., Bell, D.W., Sordella, R., Gurubhagavatula, S., Okimoto, R.A., Brannigan, B.W., Harris, P.L., Haserlat, S.M., Supko, J.G., Haluska, F.G., Louis, D.N., Christiani, D.C., Settleman, J., and Haber, D.A. (2004). Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-smallcell lung cancer to gefitinib. N Engl J Med, 350: 2129-39. 27. Paez, J.G., Janne, P.A., Lee, J.C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F.J., Lindeman, N., Boggon, T.J., Naoki, K., Sasaki, H., Fujii, Y., Eck, M.J., Sellers, W.R., Johnson, B.E., and Meyerson, M. (2004). EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science, 304: 1497-500. 28. Zhang, X. and Chang, A. (2007). Somatic mutations of the epidermal growth factor receptor and non-small-cell lung cancer. J Med Genet, 44: 166-72. 29. Mok, T.S. (2011). Personalized medicine in lung cancer: what we need to know. Nat Rev Clin Oncol, 8: 661-8. 30. Rosell, R., Moran, T., Queralt, C., Porta, R., Cardenal, F., Camps, C., Majem, M., Lopez- Vivanco, G., Isla, D., Provencio, M., Insa, A., Massuti, B., Gonzalez-Larriba, J.L., Paz- Ares, L., Bover, I., Garcia-Campelo, R., Moreno, M.A., Catot, S., Rolfo, C., Reguart, N., Palmero, R., Sanchez, J.M., Bastus, R., Mayo, C., Bertran-Alamillo, J., Molina, M.A., Sanchez, J.J., and Taron, M. (2009). Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med, 361: 958-67. 31. Shigematsu, H. and Gazdar, A.F. (2004). Mutations of EGFR in lung cancers and their implications for targeted therapy. Discov Med, 4: 444-7.
Page 3 and 4: Current Trends in Biotechnology and
Page 23: Current Trends in Biotechnology and
Page 75 and 76:
Current Trends in Biotechnology and
Page 77 and 78:
Page 79 and 80:
Page 81 and 82:
Page 83 and 84:
Page 85 and 86:
Page 87 and 88:
Page 89 and 90:
Page 91 and 92:
Page 93 and 94:
Page 95 and 96:
Page 97 and 98:
Page 99 and 100:
Page 101 and 102:
Page 103 and 104:
Page 105 and 106:
Page 107 and 108:
Page 109 and 110:
Page 111 and 112:
Page 113 and 114:
Page 115 and 116:
Page 117 and 118:
Page 119 and 120:
Page 121 and 122:
Page 123 and 124:
Page 125 and 126:
Page 127 and 128:
Page 129 and 130:
Page 131 and 132:
Page 133 and 134:
Page 135 and 136:
Page 137 and 138:
Page 139 and 140:
Page 141 and 142:
Page 143 and 144:
Page 145 and 146:
Page 147 and 148:
6th Annual Convention of Associatio
show all

d(GC) - Association of Biotechnology and Pharmacy

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?